1D09C3
1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL).
For research use only. We do not sell to patients.
- CAS No.: 791073-97-7
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
HLA-DR β
1D09C3 (2.5 µg/ mL, 24 h) significantly reduces cell countings and cell survival in HLA-DR+, but not HLA-DR- cell lines[1][2].
1D09C3 (0.1-10 µg/ mL, 4-24 h) induces a potent time- and dose-dependent death of JVM-2 and GRANTA-519 cells[1].
1D09C3 (10 µg/ mL, 4-24 h) induces cell apoptosis through a caspase-independent pathway in JVM-2 and GRANTA-519 cells[1].
1D09C3 (10 µg/ mL, 5-240 min) induces mitochondrial depolarization and generation of ROS in JVM-2 and GRANTA-519 cells[1].
1D09C3 (10 µg/ mL, 0.5-4 h) induces cell death involving activation of the JNK[1].
1D09C3 (2.5 µg/ mL, 4 h) induces cell death B-CLL cell death[1][3].
1D09C3 (10 µg/ mL, 48 h) reduces cell counts by 20% for activated T cells and by 50% for resting and activated B cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HLA-DR+ cell lines JVM-2 and GRANTA-519 and the HLA-DR cell line SU-DHL-1
-
Concentration:2.5 µg/ mL
-
Incubation Time:24 h
-
Result:Reduced the absolute number of viable cells by 3-fold and 48-fold, and the survival of tumor cells by 33-fold and 25-fold for JVM-2 and GRANTA-519, respectively
-
Cell Line:JVM-2 and GRANTA-519 cells
-
Concentration:10 µg/mL
-
Incubation Time:4, 18 and 24 h
-
Result:Showed no significant change of caspase-8, 9, 3 and RARP.
-
Cell Line:GRANTA-519 cells
-
Concentration:10 μg/mL
-
Incubation Time:0.5, 1, 2 and 4 h
-
Result:Upregulated the levels of JNK in mitochondrial and AIF in cytosolic.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:JVM-2 (1 x 106)cells xenograft mice models (NOD/SCID mice, 6-8 weeks)[1]
-
Dosage:0.01 mg/mouse (day 4), 0.1 mg/mouse (day 4)
-
Administration:Intravenous injection
-
Result:Resulted in a 20% overall survival with a median survival time of 64 days.
-
Animal Model:JVM-2 (0.25 x 106) cells xenograft mice models (NOD/SCID mice, 6-8 weeks)[1]
-
Dosage:3 x 1 mg/mouse (day 4, 7, 9) and 1 mg/mouse (day 4) for treatment of early-stage disease; 6 x 1 mg/mouse at 48-hour intervars starting onday 15 for treatment of advanced-stage disease
-
Administration:Intravenous injection
-
Result:Resulted in a 100% survival at dose up to 3 mg/mouse, and a 42% overall survival with a median survival of 99 days.
-
Animal Model:GRANTA-519 cells and KMS-11 cells xenograft mice models (NOD/SCID mice, 6-8 weeks)[1][2][3]
-
Dosage:3 x 1 mg mouse (days 1, 4, and 7) for treatment of early-stage disease and 6 x 1 mg/mouse at 48-hour intervars starting onday 7 for treatment of advanced-stage disease
-
Administration:Intravenous injection
-
Result:Resulted in a significant increase of median survival (108 days), with 27% mice being alive and disease-free at the end of the 120-day observation period
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 791073-97-7
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Carlo-Stella C, et al. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2006 Feb 1;66(3):1799-808. [Content Brief]
[2]. Carlo-Stella C, et al. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. Cancer Res. 2007 Apr 1;67(7):3269-75. [Content Brief]
[3]. Nagy ZA, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002 Aug;8(8):801-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
1D09C3 Related Classifications
HY-P991590 Related Classifications
Powered by Bioz